Deutsch English Français

Contact

EP2440577

European procedure

Quick help

Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...

News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...

Extract from the Register of European Patents

EP About this file: EP2440577

EP2440577 - TRUNCATED ACTRIIB-FC FUSION PROTEINS [Right-click to bookmark this link]
Status	The application has been withdrawn Status updated on 21.04.2017 Database last updated on 03.10.2024
Most recent event Tooltip	21.04.2017	Withdrawal of application	published on 24.05.2017 [2017/21]
Applicant(s)	For all designated states Acceleron Pharma, Inc. 128 Sidney Street Cambridge, MA 02139 / US
	[2012/16]
Inventor(s)	01 / SEEHRA, Jasbir 3 Lincoln Terrace Lexington, MA 02421-6818 / US
	02 / KUMAR, Ravindra 421 Arlington Street Acton, MA 01720 / US
	[2012/23]
Former [2012/16]	01 / SEEHRA, Jasbir 3 Lincoln Terrace Lexington, MA 02421-6818 / US
	02 / KUMAR, Ravindra 421 Arlington Street Acton, MA 01720 / US
Representative(s)	Evenson, Jane Harriet Mathys & Squire LLP The Shard 32 London Bridge Street London SE1 9SG / GB
	[N/P]
Former [2012/25]	Evenson, Jane Harriet Mathys & Squire LLP 120 Holborn London EC1N 2SQ / GB
Former [2012/16]	Zvesper, Thomas Mathys & Squire LLP 120 Holborn London EC1N 2SQ / GB
Application number, filing date	10792510.9	08.06.2010
	WO2010US37787
Priority number, date	US20090268420P	12.06.2009 Original published format: US 268420 P
	US20090280543P	03.11.2009 Original published format: US 280543 P
	[2012/16]
Filing language	EN
Procedural language	EN
Publication	Type:	A1 Application with search report
	No.:	WO2010151426
	Date:	29.12.2010
	Language:	EN
	[2010/52]
	Type:	A1 Application with search report
	No.:	EP2440577
	Date:	18.04.2012
	Language:	EN
	The application published by WIPO in one of the EPO official languages on 29.12.2010 takes the place of the publication of the European patent application.
	[2012/16]
Search report(s)	International search report - published on:	AU	29.12.2010
	(Supplementary) European search report - dispatched on:	EP	20.12.2012
Classification	IPC:	C07K14/705, A61K38/17, A61P3/00	[2012/16]
	CPC:	C12N9/12 (EP,CN,IL,KR,US); C12N15/62 (KR); C07K14/71 (EP,CN,IL,KR,US); A61K38/00 (EP,CN,IL,US); A61K38/17 (KR); A61P1/16 (EP,IL); (+) A61P11/00 (EP,IL); A61P15/10 (EP,IL); A61P17/02 (EP,IL); A61P19/02 (EP,IL); A61P19/10 (EP,IL); A61P21/00 (EP,IL); A61P21/02 (EP,IL); A61P21/04 (EP,IL); A61P25/28 (EP,IL); A61P29/00 (EP,IL); A61P3/00 (EP,IL); A61P3/02 (EP,IL); A61P3/04 (EP,IL); A61P3/06 (EP,IL); A61P3/08 (EP,IL); A61P3/10 (EP,IL); A61P35/00 (EP,IL); A61P43/00 (EP,IL); A61P5/26 (EP,IL); A61P5/50 (EP,IL); A61P9/10 (EP,IL); A61P9/12 (EP,IL); C07H21/04 (EP,IL,US); C07K14/475 (EP,IL,KR,US); C07K14/705 (KR); C12N5/0682 (CN); C12Y207/1103 (EP,CN,IL,US); C07K2319/30 (EP,CN,IL,KR,US); C12N2510/02 (EP,CN,IL,KR,US); G01N2800/042 (KR) (-)
Designated contracting states	AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR [2012/16]
Extension states	BA	12.01.2012
	ME	12.01.2012
	RS	12.01.2012
Title	German:	VERKÜRZTE ACTRIIB-FC-FUSIONSPROTEINE	[2012/16]
	English:	TRUNCATED ACTRIIB-FC FUSION PROTEINS	[2012/16]
	French:	PROTÉINES DE FUSION ACTRIIB-FC TRONQUÉES	[2012/16]
Entry into regional phase	12.01.2012	National basic fee paid
	12.01.2012	Search fee paid
	12.01.2012	Designation fee(s) paid
	12.01.2012	Examination fee paid
Examination procedure	12.01.2012	Examination requested [2012/16]
	05.11.2013	Amendment by applicant (claims and/or description)
	16.04.2014	Despatch of a communication from the examining division (Time limit: M06)
	22.01.2015	Reply to a communication from the examining division
	16.09.2015	Despatch of a communication from the examining division (Time limit: M06)
	22.04.2016	Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time
	22.06.2016	Reply to a communication from the examining division
	18.04.2017	Application withdrawn by applicant [2017/21]
	18.04.2017	Cancellation of oral proceeding that was planned for 09.05.2017
	09.05.2017	Date of oral proceedings (cancelled)
Divisional application(s)	EP17166621.7 / EP3290439
	EP20193499.9
	The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is 16.04.2014
Request for further processing for:	The application is deemed to be withdrawn due to failure to reply to the examination report
	22.06.2016	Request for further processing filed
	22.06.2016	Full payment received (date of receipt of payment) Request granted
	05.07.2016	Decision despatched
	The application is deemed to be withdrawn due to failure to reply to the examination report
	22.01.2015	Request for further processing filed
	22.01.2015	Full payment received (date of receipt of payment) Request granted
	30.01.2015	Decision despatched
	The application is deemed to be withdrawn due to failure to reply to the Extended European Search Report/Written Opinion of the International Searching Authority/International Preliminary Examination Report/Supplementary international search report/Supplementary European search report
	05.11.2013	Request for further processing filed
	05.11.2013	Full payment received (date of receipt of payment) Request granted
	14.11.2013	Decision despatched
Fees paid	Renewal fee
	26.06.2012	Renewal fee patent year 03
	27.06.2013	Renewal fee patent year 04
	30.06.2014	Renewal fee patent year 05
	29.06.2015	Renewal fee patent year 06
	27.06.2016	Renewal fee patent year 07
Opt-out from the exclusive Tooltip competence of the Unified Patent Court	See the Register of the Unified Patent Court for opt-out data
	Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:	Search	[XP]WO2010019261 (ACCELERON PHARMA INC [US], et al) [XP] 1-44 * sequences 2, 5, 28, 30 *;
		[E]WO2010083034 (ACCELERON PHARMA INC [US], et al) [E] 1-11,13-44 * sequence 5 * * example 1 * * sequence 23 *;
		[E]WO2011020045 (ACCELERON PHARMA INC [US], et al) [E] 1-44* sequences 1, 35 *
	International search	[X]US2001039036 (MATHEWS LAWRENCE S [US], et al);
		[X]WO2006012627 (ACCELERON PHARMA INC [US], et al);
		[X]WO2006020884 (WYETH CORP [US], et al);
		[X]WO2008076437 (ACCELERON PHARMA INC [US], et al);
		[X]WO2008097541 (ACCELERON PHARMA INC [US], et al);
		[X]WO2008109167 (AMGEN INC [US], et al);
		[X]WO2008151078 (WYETH CORP [US], et al);
		[XP]US2010068215 (SEEHRA JASBIR [US], et al);
		[E]US2010183624 (SEEHRA JASBIR [US], et al);
		[XP] - SAKO D. ET AL., "Characterization of the Ligand Binding Functionality of the Extracellular Domain of Activin Receptor Type IIB", THE JOURNAL OF BIOLOGICAL CHEMISTRY, (201004), vol. 285, no. 27, pages 21037 - 21048, XP008148640 DOI: http://dx.doi.org/10.1074/jbc.M110.114959
		[XP] - CADENA S.M. ET AL., "Administration of a Soluble Activin Type IIB Receptor Promotes Skeletal Muscle Growth Independent of Fiber Type", JOURNAL OF APPLIED PHYSIOLOGY, (201005), pages 1 - 25, XP008148636 DOI: http://dx.doi.org/10.1152/japplphysiol.00866.2009

The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.

Legal notice
Terms of use
24.2.25; 34p